CD19 and neoplasm: The surviving animals in the Her2-bridging CAR19 T cell treated cohort were rested until day 55 (post tumor challenge) and then 4 mice were rechallenged with 1 x 106 Nalm6 cells to investigate whether the remaining CAR T cell pool could react to directly presented CD19 antigen.